All In Biotech

Drug Trial Radar · NCT00758498

Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder

A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder

Last checked: Nov 20, 2026Latest source record: Jul 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 427 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

427

Actual

Start

Sep 2008

Primary completion

Feb 2009

Study completion Feb 2009

Sponsor

Lead sponsor
CephalonIndustry
Sponsor type
Industry
First posted
Sep 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-group study of armodafinil and placebo treatment in healthy subjects with excessive sleepiness associated with jet lag disorder.

Conditions

  • Excessive Sleepiness

Interventions

  • armodafinilDrug

    50 mg/day orally, once daily in the morning for 3 days

  • armodafinilDrug

    150 mg/day orally, once daily in the morning for 3 days

  • placeboDrug

    placebo tablets, once daily in the morning for 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Sleep Latency (Minutes) From the Multiple Sleep Latency Test (MSLT)- Average of Four Scheduled Naps Across Days 1 and 2Time frame: Days 1 and 2
  2. Average of Patient Global Impression of Severity (PGI-S) of General Condition Ratings Across Days 1 and 2Time frame: Days 1 and 2

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Neurotrials Research, Inc.

    Atlanta, Georgia

  • Community Research

    Crestview, Kentucky

  • Clinilabs, Inc.

    New York, New York

  • SleepMed of South Carolina

    Columbia, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.